CHMP adopts a positive opinion for change to the terms of the marketing authorisation for Tremfya (guselkumab) – Johnson & Johnson
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for Tremfya (guselkumab). The marketing… read more.




